Immunization with inactivated whole virus particle influenza virus vaccines improves the humoral response landscape in cynomolgus macaques

BY Chua; T Sekiya; M Koutsakos; N Nomura; LC Rowntree; THO Nguyen; HA McQuilten; M Ohno; Y Ohara; T Nishimura; M Endo; Y Itoh; JR Habel; KJ Selva; AK Wheatley; BD Wines; PM Hogarth; SJ Kent; AW Chung; DC Jackson; LE Brown; M Shingai; K Kedzierska; H Kida

Journal article

Immunization with inactivated whole virus particle influenza virus vaccines improves the humoral response landscape in cynomolgus macaques

BY Chua, T Sekiya, M Koutsakos, N Nomura, LC Rowntree, THO Nguyen, HA McQuilten, M Ohno, Y Ohara, T Nishimura, M Endo, Y Itoh, JR Habel, KJ Selva, AK Wheatley, BD Wines, PM Hogarth, SJ Kent, AW Chung, DC Jackson Show all

Plos Pathogens | Published : 2022

DOI: 10.1371/journal.ppat.1010891

Download PDF

Abstract

Although antibody-inducing split virus vaccines (SV) are currently the most effective way to combat seasonal influenza, their efficacy can be modest, especially in immunologically-naïve individuals. We investigated immune responses towards inactivated whole influenza virus particle vaccine (WPV) formulations, predicated to be more immunogenic, in a nonhuman primate model, as an important step towards clinical testing in humans. Comprehensive analyses were used to capture 46 immune parameters to profile how WPV-induced responses differed to those elicited by antigenically-similar SV formulations. Naïve cynomolgus macaques vaccinated with either monovalent or quadrivalent WPV consistently indu..

View full abstract

University of Melbourne Researchers

Brendon Chua Author

Toshiki Sekiya Author

Marios Koutsakos Author

Louise Rowntree Author

Related Projects (2)

LIMITING THE IMPACT OF INFLUENZA

The development of better ways to prevent and treat influenza infection will be a major step forward in lessening the impact of the virus in..

UNDERSTANDING UNIVERSAL IMMUNITY TO INFLUENZA VIRUSES

A/Prof Kedzierska’s work combines cutting-edge basic research with unique clinical studies to define how to generate protective immunity aga..

Grants

Awarded by University of Melbourne

Funding Acknowledgements

The project was supported by the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID; JP19fm0108008 to HK and MS), the Japan Program for Infectious Diseases Research and Infrastructure (JIDRI; JP20wm0125008 to HK and MS), a Research Program on Emerging and Re-emerging Infectious Diseases (21fk0108142 to HK and MS) from the Japan Agency for Medical Research and Development (AMED), the GI-CoRE Program of Hokkaido University, the Doctoral Program for World-leading Innovative & Smart Education Program (WISE; 1801 to MS) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT). MO, MS and YI were supported by grants from JSPS KAKENHI (grant numbers 21H02376, 17K15367, 18K07135 and 15H04720, respectively). The work was partly funded by an Australian National Health and Medical Research Council (NHMRC) Program Grant (1071916) awarded to KK, DCJ, LEB. KK was supported by an NHMRC Senior Research Fellowship Level B (#1102792), NHMRC Investigator Grant (#1173871) and a Dame Kate Campbell Fellowship from The University of Melbourne. BYC was supported by a CR Roper Fellowship from the University of Melbourne. THON and MK was supported by NHMRC Emerging Leadership Level 1 Investigator Grants (#1194036 and #1195698, respectively). JRH was supported by a Melbourne Research Scholarship from The University of Melbourne. The work of PMH and BDW were supported by an NHMRC Project grant (#GNT1145303). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.